Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Status:
Terminated
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in
adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3
months treatment with hydroxychloroquine.
Phase:
Phase 2
Details
Lead Sponsor:
Corbus Pharmaceuticals Inc.
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) University of Pennsylvania